A Survey on Congestion Control Protocols for CoAP

The Internet of things (IoT) comprises things interconnected through the internet with unique identities. Congestion management is one of the most challenging tasks in networks. The Constrained Application Protocol (CoAP) is a low-footprint protocol designed for IoT networks and has been defined by IETF. In IoT networks, CoAP nodes have limited network and battery resources. The CoAP standard has an exponential backoff congestion control mechanism. This backoff mechanism may not be adequate for all IoT applications. The characteristics of each IoT application would be different. Further, the events such as unnecessary retransmissions and packet collision caused due to links with high losses and packet transmission errors may lead to network congestion. Various congestion handling algorithms for CoAP have been defined to enrich the performance of IoT applications. Our paper presents a comprehensive survey on the evolution of the congestion control mechanism used in IoT networks. We have classified the protocols into RTO-based, queue-monitoring, and rate-based. We review congestion avoidance protocols for CoAP networks and discuss directions for future work

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Analysis of Receiver Window Control in presence of a fair router

Receiver Window Control is a mechanism used to change the TCP advertised window so as to manipulate the bandwidth sharing of multiple TCP sessions. The research on receiver window control so far does not analyze behavior of the receiver window in the presence of packet drops at a fair router. In this paper, we analyze receiver window control in the presence of a modified RED-DT (Random Early Detection with Dynamic Thresholds) router. We show that the receiver window control mechanism is goodput preserving and does not adversely impact competing traffic.© IEE

Analysis of Receiver Window Control in Presence of a Fair Router

Receiver Window Control is a mechanism used to change the TCP advertised window so as to manipulate the bandwidth sharing of multiple TCP sessions. The research on receiver window control so far [3],[5],[6] does not analyze behavior of receiver window in the presence of packet drops at a fair router. In this paper, we analyze receiver window control in the presence of a modified RED-DT (Random Early Detection with Dynamic Thresholds) [9] router. We show that receiver window control mechanism is goodput preserving and does not adversely impact competing traffic. I

Architecting protocol stack optimizations on mobile devices

Abstract — Applications using traditional protocol stacks (e.g TCP/IP) from wired networks do not function efficiently in mobile wireless scenarios. This is primarily due to the layered architecture and implementation of protocol stacks. Cross layer feedback is one of the mechanisms to improve the performance of a layered stack, in mobile wireless environments. For example, transport layer retransmissions could be reduced by making it aware of network disconnections or handoff events. However, since the protocol stack is an integral part of the operating system, any such cross layer modification to the stack should not impact its efficiency, correctness and maintainability. An appropriate architecture would help ensure that cross layer modifications confirm to this requirement. In this paper, we present an architecture ECLAIR for cross layer feedback. As compared to other approaches, ECLAIR requires minimal or no modification to the stack. To evaluate the efficiency of cross layer architectures, we identify time/space complexity, design complexity, user-kernel crossing and data path delay as performance metrics. We validate and evaluate ECLAIR through a prototype implementation and experiments. Our results and analysis show that ECLAIR is an efficient cross layer architecture. To enhance the efficiency of ECLAIR, we propose a sub-architecture to reduce the runtime overheads. We also present a design guide for cross layer optimizations using ECLAIR. I

- Fully completed

We study how SVM-based binary classifiers are used for multi-way classification. We present the results of experiments run on various UCI and KDD datasets, using the SVM Light package. The methods evaluated are 1-versus-1, 1-versus-many and Erroc Correcting Output Coding (ECOC)